Boston Scientific Corporation: Carcinoma, Hepatocellular trials

The registry lists 12 Carcinoma, Hepatocellular studies with Boston Scientific Corporation as lead sponsor. 2 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 2 2Phase 3 2No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.Not yet recruitingNCT07669727
• TheraSphere Japan Pre-Market StudyRecruitingNCT07377487Not applicable
• Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver MalignanciesCompletedNCT03291379Early Phase 1Results posted
• A Study of ONCO-DOX in Locally Advanced Hepatocellular CarcinomaTerminatedNCT02460991Phase 3Results posted
• Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal VeinTerminatedNCT01887717Phase 3Results posted
• Microparticle Enhanced Cytotoxic Transarterial Embolization Therapy in Hepatocellular CarcinomaCompletedNCT01798134Not applicableResults posted
• Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver CancerCompletedNCT01556490Not applicableResults posted
• TheraSphere With Durvalumab and Tremelimumab for HCCActive, not recruitingNCT05063565Phase 2
• Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT04069468
• Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With DoxorubicinWithdrawnNCT03452553Not applicable
• A TheraSphere® Advanced Dosimetry Retrospective Global Study in HCCCompletedNCT03295006
• Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead EmbolisationCompletedNCT00261378Phase 2